EP0802908A4 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
EP0802908A4
EP0802908A4 EP96903709A EP96903709A EP0802908A4 EP 0802908 A4 EP0802908 A4 EP 0802908A4 EP 96903709 A EP96903709 A EP 96903709A EP 96903709 A EP96903709 A EP 96903709A EP 0802908 A4 EP0802908 A4 EP 0802908A4
Authority
EP
European Patent Office
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96903709A
Other languages
German (de)
French (fr)
Other versions
EP0802908A1 (en
Inventor
Jerry Leroy Adams
Ravi Shanker Garigipati
John Cheung-Lun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0802908A1 publication Critical patent/EP0802908A1/en
Publication of EP0802908A4 publication Critical patent/EP0802908A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
EP96903709A 1995-01-12 1996-01-11 Novel compounds Withdrawn EP0802908A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US374278 1989-06-30
US37252195A 1995-01-12 1995-01-12
US37427895A 1995-01-18 1995-01-18
US48334895A 1995-06-07 1995-06-07
US483348 1995-06-07
PCT/US1996/001094 WO1996021654A1 (en) 1995-01-12 1996-01-11 Novel compounds
US372521 2003-02-21

Publications (2)

Publication Number Publication Date
EP0802908A1 EP0802908A1 (en) 1997-10-29
EP0802908A4 true EP0802908A4 (en) 2001-04-11

Family

ID=27409084

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96903709A Withdrawn EP0802908A4 (en) 1995-01-12 1996-01-11 Novel compounds

Country Status (14)

Country Link
EP (1) EP0802908A4 (en)
JP (1) JPH10512264A (en)
KR (1) KR19980701374A (en)
AU (1) AU709370B2 (en)
BR (1) BR9607097A (en)
CA (1) CA2210322A1 (en)
CZ (1) CZ219597A3 (en)
FI (1) FI972970A (en)
HU (1) HUP0102677A3 (en)
MX (1) MX9705296A (en)
NO (1) NO973231L (en)
NZ (1) NZ302117A (en)
PL (1) PL321292A1 (en)
WO (1) WO1996021654A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
WO1997025047A1 (en) * 1996-01-11 1997-07-17 Smithkline Beecham Corporation Novel cycloalkyl substituded imidazoles
US6096748A (en) * 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
WO1997035856A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
EP0956018A4 (en) 1996-08-21 2000-01-12 Smithkline Beecham Corp Imidazole compounds, compositions and use
US5939069A (en) 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
IL129928A0 (en) 1996-11-19 2000-02-29 Amgen Inc Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
AU730295B2 (en) * 1996-11-20 2001-03-01 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
ZA9711092B (en) * 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
AU8381098A (en) 1997-07-02 1999-01-25 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (en) * 1997-07-02 2001-07-04 Smithkline Beecham Corp IMIDAZOL SUBSTITUTE COMPOSITE, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR SUPREPARATION
JP2001518507A (en) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション New cycloalkenyl substituted compounds
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
JP2001521934A (en) * 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Aromatic heterocyclic compounds as anti-inflammatory drugs
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
EP1080087A4 (en) 1998-05-22 2001-11-21 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
JP2002528506A (en) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション Pyridin-4-yl or pyrimidin-4-yl substituted pyrazine
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
ES2241675T3 (en) 1999-11-23 2005-11-01 Smithkline Beecham Corporation 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA COMPOUNDS AS CSPB / P38 QUINASA INHIBITORS.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ES2249309T3 (en) 1999-11-23 2006-04-01 Smithkline Beecham Corp COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2036891A3 (en) 2001-06-11 2009-03-25 Vertex Pharmaceuticals Incorporated Isoquinoline inhibitors of P38
PL210470B1 (en) * 2001-10-22 2012-01-31 Mitsubishi Tanabe Pharma Corp 4-imidazolin-2-one compounds
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
RU2351590C2 (en) 2003-02-10 2009-04-10 Вертекс Фармасьютикалз Инкорпорейтед Method of producing diarylamine
WO2005000405A2 (en) * 2003-06-06 2005-01-06 The Trustees Of The University Of Pennsylvania P38 kinase inhibitor compositions and methods of use
EP2396302A2 (en) 2009-02-13 2011-12-21 Vertex Pharmceuticals Incorporated Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
US20110086891A1 (en) 2009-02-13 2011-04-14 Vertex Pharmaceuticals Incorporated Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide)
CN113350353A (en) * 2015-03-23 2021-09-07 墨尔本大学 Treatment of respiratory diseases
JP2016193861A (en) * 2015-03-31 2016-11-17 国立大学法人山梨大学 Pharmaceutical compositions for inhibiting mast cell activation
DK3368052T3 (en) 2015-10-27 2022-03-14 Childrens Hospital Med Ct USE OF MAPK INHIBITORS TO REDUCE THE LOSS OF HEMATOPOETIC STEM CELLS DURING EX VIVO CULTIVATION AND GENE MANIPULATION
AU2019374731A1 (en) * 2018-11-07 2021-05-27 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107963A (en) * 1986-06-04 1988-05-12 Toyama Chem Co Ltd Novel imidazole derivative and salt thereof
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
WO1995002591A1 (en) * 1993-07-16 1995-01-26 Smithkline Beecham Corporation Tri-substituted imidazoles having multiple therapeutic properties
WO1996021452A1 (en) * 1995-01-09 1996-07-18 Smithkline Beecham Corporation Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
WO1996040143A1 (en) * 1995-06-07 1996-12-19 Smithkline Beecham Corporation Imidazole compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107963A (en) * 1986-06-04 1988-05-12 Toyama Chem Co Ltd Novel imidazole derivative and salt thereof
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors
WO1995002591A1 (en) * 1993-07-16 1995-01-26 Smithkline Beecham Corporation Tri-substituted imidazoles having multiple therapeutic properties
WO1996021452A1 (en) * 1995-01-09 1996-07-18 Smithkline Beecham Corporation Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
WO1996040143A1 (en) * 1995-06-07 1996-12-19 Smithkline Beecham Corporation Imidazole compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOEHM ET AL: "1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 39, no. 20, 27 September 1996 (1996-09-27), pages 3929 - 3937, XP002103149, ISSN: 0022-2623 *
PATENT ABSTRACTS OF JAPAN vol. 012, no. 353 (C - 530) 21 September 1988 (1988-09-21) *
See also references of WO9621654A1 *

Also Published As

Publication number Publication date
MX9705296A (en) 1997-10-31
CA2210322A1 (en) 1996-07-18
NO973231L (en) 1997-09-11
HUP0102677A3 (en) 2002-09-30
EP0802908A1 (en) 1997-10-29
FI972970A (en) 1997-09-11
NZ302117A (en) 1999-10-28
HUP0102677A2 (en) 2002-04-29
JPH10512264A (en) 1998-11-24
FI972970A0 (en) 1997-07-11
PL321292A1 (en) 1997-11-24
WO1996021654A1 (en) 1996-07-18
KR19980701374A (en) 1998-05-15
AU709370B2 (en) 1999-08-26
NO973231D0 (en) 1997-07-11
CZ219597A3 (en) 1998-03-18
BR9607097A (en) 1997-11-11
AU4770496A (en) 1996-07-31

Similar Documents

Publication Publication Date Title
AP9701021A0 (en) Novel compounds
PL321292A1 (en) Novel xchemical compounds
GB9507203D0 (en) Novel compounds
GB9509164D0 (en) Novel compounds
GB9503717D0 (en) Novel compounds
GB9508957D0 (en) Novel compounds
GB9515056D0 (en) Novel compounds
GB9500262D0 (en) Novel compounds
GB9508964D0 (en) Novel compounds
GB9502052D0 (en) Novel compounds
GB9503172D0 (en) Novel compounds
GB9503173D0 (en) Novel compounds
GB9503177D0 (en) Novel compounds
GB9503179D0 (en) Novel compounds
GB9503612D0 (en) Novel compounds
GB9503647D0 (en) Novel compounds
GB9503648D0 (en) Novel compounds
GB9504400D0 (en) Novel compounds
GB9504718D0 (en) Novel compounds
GB9507432D0 (en) Novel compounds
GB9508010D0 (en) Novel compounds
GB9508327D0 (en) Novel compounds
GB9509165D0 (en) Novel compounds
GB9508956D0 (en) Novel compounds
ZA96121B (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 970811

A4 Supplementary search report drawn up and despatched

Effective date: 20010227

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 401/04 A, 7C 07D 403/04 B, 7A 61K 31/44 B, 7A 61K 31/47 B, 7A 61K 31/415 B, 7A 61K 31/505 B, 7C 07D 405/14 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1003887

Country of ref document: HK